第3回DIA総合ワークショップ
The Third Multitrack Workshop in Japan

医薬品開発における産官学の役割分担と真の協働に向けて
How Could Companies, Regulators and Academia Better Collaborate in Pharmaceutical Development?

データ・ドキュメント新時代への招待
Invitation to New Era of Data and Documents

～「より有効で」「より安全な」医薬品を「より早く」患者の皆様に届けること～
Collaboration to Fulfill Our Joint Mission of Delivering to Patients Medications of Greater Efficacy and Greater Safety with Greater Speed

生物統計学は薬の開発にいかに貢献できるか
Value-added Contribution of Biostatistics to Drug Development

東京コンファレンスセンター・品川
Tokyo Conference Center - Shinagawa

2006年10月5日（木）、6日（金）
October 5-6, 2006

Program chairman
YASUO OASHI, PhD
University of Tokyo

Program vice-chairman
YUIICHI KUBO
Daiichi Sankyo Inc.

Endorsement by MHLW, PMDA and JPMA

REGISTER ONLINE! www.diahome.org
Drug Information Association, LLC
Level 2, Toranomon 10 Mori Building, 1-18-1 Toranomon, Minato-ku, Tokyo 105-0001 Japan
Tel: +81-3-5511-1131 Fax: +81-3-5511-0100 Email: diajapan@diajapan.org
Dear Colleagues and Friends,

On behalf of the program committee, it is my pleasure and honor to welcome you to the third multitrack workshop in Japan, **How Could Companies, Regulators and Academia Better Collaborate in Pharmaceutical Development?** Following the past two successful multitrack meetings in Japan, we have organized this meeting with three multitrack sessions, plenary session and “Ask the Regulators.”

The plenary session of this timely meeting, scheduled in the afternoon of the second day, will have two keynote presentations, followed by discussion on how to be successful in pharmaceutical development, overcoming an extremely demanding environment in terms of knowledge, expertise, cost and time, by collaboration of industry, academia and regulatory bodies. The highly acclaimed “Ask the Regulators” open discussion period follows this plenary. After presentations on clinical safety management, experts from regulatory agencies will answer questions about pharmaceutical development and safety management.

With three concurrent tracks of content management, regulatory and safety management, and biostatistics, we will discuss possible collaboration in the most advanced topics. Track A, **Invitation to New Era of Data and Documents,** covers data management, medical writing and content management. In Track B with the theme of **Collaboration to Fulfill Our Joint Mission of Delivering to Patients Medications of Greater Efficacy and Greater Safety with Greater Speed,** areas of regulatory affairs, safety management and pharmacovigilance will be discussed. In **Track C, Value-added Contribution of Biostatistics to Drug Development,** topics in biostatistics will be discussed. All meeting participants will be able to attend sessions in any of these tracks.

Tabletop exhibits will also be open throughout the meeting with accessible layout and time schedule. A wine and cheese reception will be held on the evening of the first day. The informal mini-sessions, **What is the DIA World?** and open discussion session, **Behind the Scenes of Biostatistics – Q&A** (Chair: Yasuo Ohashi, PhD, University of Tokyo) will be also held in parallel. We hope these activities will provide attendees the opportunity to obtain the most current information.
PLENARY SESSION

PART 1: DIA Welcome – Thursday, October 5, 9:10-9:30
Chair: Yasuo Ohashi, PhD, Professor, Department of Biostatistics, School of Health Sciences and Nursing, University of Tokyo, Japan
Speakers: David M. Maola, Esq., Executive Director, Drug Information Association, USA and Takatoshi Sato, Chair, DIA Advisory Council of Japan and HyCLIPS Co., Ltd., Japan

PART 2: Keynote Presentations and Panel Discussion
Friday, October 6, 12:30-14:00
Chair: Yasuo Ohashi, PhD, Professor, Department of Biostatistics, School of Health Sciences and Nursing, University of Tokyo, Japan

Keynote presenters at the plenary session will be Dr. Koji Kawakami, Professor of Pharmacoepidemiology, Kyoto University, former FDA biologists reviewer, and Mr. Takeo Ozawa, POC Clinical Research, who worked as an organizer of Japan’s first gene therapy clinical study and currently supports venture companies. The discussion will focus on how industry, academia and regulatory bodies can collaborate in the areas of advanced medical fields including topics of investigator-initiated clinical trials and training of reviewers.

ASK THE REGULATORS – Friday, October 6, 14:15-17:00
Chairs: Makoto Shiragami, PhD, Professor, Social and Administrative Pharmacy Science, College of Pharmacy, Nihon University, Japan and E. Stewart Geary, MD, Deputy Director, Corporate Regulatory Compliance and Quality Assurance Headquarters, Eisai Co., Ltd., Japan

Following presentations on clinical safety management, experts of regulatory agencies will answer questions about pharmaceutical development and safety management.

GENERAL INFORMATION

Registration: Registration will start at 8:15 on the 5th floor
Exhibition: Thursday, October 5, 10:00-20:00 at the Foyer on the 5th floor Friday, October 6, 9:00-17:00 at the Foyer on the 5th floor
Reception: Thursday, October 5, 18:00-20:00 in the Foyer on 5th floor. Two kinds of mini-sessions will be held during the time of the reception.
1) What is the DIA World?
Thursday, October 5, 19:00-20:30 in Ballroom A. This session is open to the newcomers/freshmen to DIA.
2) Behind the Scenes of Biostatistics – Q&A
Thursday, October 5, 19:00-20:30 in Room 406. This session is open to the participants who are interested in statistics.
Travel and Hotel: Please make your airline reservations as early as possible to ensure availability. The most convenient airport to this hotel is Narita Airport. There are a limited number of rooms at the Le Meridien Pacific Tokyo (Hotel Pacific Tokyo) at the reduced rates shown below (includes taxes and breakfast.) Please make your room reservations as soon as possible.
- Single ¥19,950/night
- Twin/Single Use ¥22,260/night
- Twin ¥23,215/night

To reserve your room, please contact the Le Meridien Pacific Tokyo by telephone at +81-(0)3-3445-6711, or by fax at +81-(0)3-3445-5137 and mention the DIA Workshop. The Le Meridien Pacific Tokyo is located at 3-13-3, Takanawa, Minato-ku, Tokyo 108-8567.

WHAT TO SEE IN JAPAN

Recommended traditional local package tours are shown below. Please note that a tour desk will not be available on site at this workshop. You can make reservations at http://www.jtbgmt.com/sunrisetour/te5/

- **Tokyo Afternoon Tour** (Daily 3.6 Hours) ¥5,000 (child 6-11 yrs. ¥3,800)
  (Seaside Top, Sumida River Cruise, Asakusa Kannon Temple, Nakamise Shopping Street, Imperial Palace Plaza)

- **Dynamic Tokyo** (Daily 8.2 Hours) ¥12,000 (child 6-11 yrs. ¥9,800)
  (Tokyo Tower, Tea Ceremony and Bonsai Trees, Barbecue Lunch, National Diet Building (drive by), Imperial Palace Plaza, Ginza Shopping District (drive through), Sumida River Cruise, Asakusa Kannon Temple, Nakamise Shopping Street)

- **Shinkansen Tour**
  A. Mt. Fuji (¥10,000.- or up)
  B. Hakone (¥10,000.- or up)
  C. Nikko World Heritage (¥11,500.- or up)
  D. Kamakura Walking Tour (¥11,000.- or up)

Contact and Tabletop Exhibit Information
For meeting and tabletop exhibit information, contact Yuka Nakamura at the Drug Information Association, LLC office in Tokyo by telephone +81-(0)-5511-1131, fax +81-(0)-5511-0100 or email diajapan@diajapan.org
If you are interested in obtaining space for a tabletop exhibit, please check the box in the REGISTRATION FEE area on page 7 or 8.

KEYNOTE #1
Scientific Review and Clinical Development of Advanced Therapeutics and Biologics
Koji Kawakami, MD, PhD, Professor, Department of Pharmacoepidemiology, Kyoto University Graduate School of Medicine and Public Health, Japan

KEYNOTE #2
Issue of Cooperation with Industry, Government and Academic Institute on Advanced Biomedical Research, and the Meaning of R&D Support for Bioventure Companies
Takeo Ozawa, President & CEO, POC Clinical Research Inc., Japan

基調講義には、FDA での生物製剤審査官の経験もお持ちの川上浩司氏(京都大学薬剤学教授)と、日本初の遺伝子治療を中心として立ち上げ、現在はベンチャー支援をなされている小澤健夫氏 (POC クリニカルリサーチ)をお招きします。どうに先端医療を対象として、研究者主導試験の活用・審査官の養成も含め産官学の真の協働について講演いたします。

■基調講義-1：『先端医療・生物製剤における科学的審査と臨床開発について』
川上浩司 (京都大学薬剤学教授)

■基調講義-2：『先端医療における産官学連携の課題とベンチャー支援の意義（仮題）』
小澤健夫（POC クリニカルリサーチ株式会社代表取締役社長）

安全評価に関わる問題提示の講演に引き続き、当局の専門技官から開発・安全性評価に関する質問にお答え頂きます。
## Congress at a Glance

**Thursday, October 5, 2006**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15-9:10</td>
<td>Registration</td>
</tr>
<tr>
<td>9:10-9:30</td>
<td><strong>PLENARY SESSION – Part 1: DIA Welcome</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: Yasuo Ohashi, PhD, Professor, Department of Biostatistics, School of Health Sciences and Nursing, University of Tokyo, Japan</td>
</tr>
<tr>
<td></td>
<td>Speakers: David M. Maola, Esq., Executive Director, Drug Information Association, USA and Takatoshi Sato, Chair, DIA Advisory Council of Japan and HyCLIPS Co., Ltd., Japan</td>
</tr>
<tr>
<td>9:30-11:30</td>
<td><strong>Concurrent Sessions</strong></td>
</tr>
<tr>
<td></td>
<td><strong>TRACK A</strong></td>
</tr>
<tr>
<td></td>
<td>Invitation to a New Era of Data and Documents</td>
</tr>
<tr>
<td></td>
<td>Track Chair: Keiji Sawamukai, Manager, Data Management, Sankyo Co., Ltd., Japan</td>
</tr>
<tr>
<td></td>
<td><strong>TRACK B</strong></td>
</tr>
<tr>
<td></td>
<td>Collaboration to Fulfill Our Joint Mission of Delivering to Patients Medications of Greater Efficacy and Greater Safety with Greater Speed</td>
</tr>
<tr>
<td></td>
<td>Track Chairs: Makoto Shiragami, PhD, Professor, Social and Administrative Pharmacy Science, College of Pharmacy, Nihon University, Japan and E. Stewart Geary, MD, Deputy Director, Corporate Regulatory Compliance and Quality Assurance Headquarters, Eisai Co., Ltd., Japan</td>
</tr>
<tr>
<td></td>
<td><strong>TRACK C</strong></td>
</tr>
<tr>
<td></td>
<td>Value-added Contribution of Biostatistics to Drug Development</td>
</tr>
<tr>
<td></td>
<td>Track Chair: Hiroshi Maeda, Department Manager, Data Management Department, Clinical Development Division, Medical Support Business Unit, Bellsystem24, Inc., Japan</td>
</tr>
<tr>
<td>11:30-1:00</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>11:30-12:30</td>
<td><strong>SESSION 1-2</strong></td>
</tr>
<tr>
<td></td>
<td>Seamless Data Flow</td>
</tr>
<tr>
<td></td>
<td>Chair: Hidefumi Nakamura, MD, PhD, Director, Division of Clinical Research, National Center for Child Health and Development, Japan</td>
</tr>
<tr>
<td></td>
<td>9:30-10:10</td>
</tr>
<tr>
<td></td>
<td>Electronic Situation for Clinical Study Data on the Institution Side</td>
</tr>
<tr>
<td></td>
<td>Takahiro Kuchi, Director and Professor, University Hospital Medical Information Network (UMIN) Center, The University of Tokyo Hospital, Japan</td>
</tr>
<tr>
<td></td>
<td>10:10-10:50</td>
</tr>
<tr>
<td></td>
<td>Introduction of EDC Example in Clinical Study</td>
</tr>
<tr>
<td></td>
<td>Yuko Saito, MS, RN, Principal Reviewer, Office of New Drug I, PMDA, Japan</td>
</tr>
<tr>
<td></td>
<td>10:50-11:30</td>
</tr>
<tr>
<td></td>
<td>Ideal EDC System from the Medical Institution Standpoint: An Experience from an Investigator-initiated Clinical Trial</td>
</tr>
<tr>
<td></td>
<td>Yoichi Ishikawa, Senior Pharmacist, Department of Pharmacy, National Center for Child Health and Development, Japan</td>
</tr>
<tr>
<td>13:00-15:00</td>
<td><strong>SESSION 3</strong></td>
</tr>
<tr>
<td></td>
<td>Regulatory Updates</td>
</tr>
<tr>
<td></td>
<td>Chairs: Hitoshi Matsui, Medical and Pharmaceutical Collaborative Solution Department II, CAC Corporation, Japan, Atsushi Tamaru, PhD, Manager, Clinical Development Coordination, Kyowa Hakko Kogyo Co., Ltd., Japan</td>
</tr>
<tr>
<td></td>
<td>13:00-13:40</td>
</tr>
<tr>
<td></td>
<td>FDA Education and Training of NDA Reviewers</td>
</tr>
<tr>
<td></td>
<td>Nancy D. Smith, PhD, Director, Office of Training and Communications, CDER, FDA, USA</td>
</tr>
<tr>
<td></td>
<td>13:40-14:00</td>
</tr>
<tr>
<td></td>
<td>Academia: Training Courses in Regulatory Science</td>
</tr>
<tr>
<td></td>
<td>Shunsuke Oto, PhD, Associate Professor, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan</td>
</tr>
<tr>
<td></td>
<td>14:00-14:30</td>
</tr>
<tr>
<td></td>
<td>PMDA: Education and Training of Its Personnel</td>
</tr>
<tr>
<td></td>
<td>Shigeki Tsuda, Division Director, International Affairs and Human Resources Development Division, PMDA, Japan</td>
</tr>
<tr>
<td></td>
<td>14:30-15:00</td>
</tr>
<tr>
<td></td>
<td>Training: A Continuum for Compliance and Global Regulatory Strategy</td>
</tr>
<tr>
<td></td>
<td>Christopher R. Griffin, Executive Director, Global Regulatory Affairs, Schering-Plough, USA</td>
</tr>
<tr>
<td>15:00-16:30</td>
<td><strong>SESSION 3-4</strong></td>
</tr>
<tr>
<td></td>
<td>Statistical Contribution to the Drug Development Strategy</td>
</tr>
<tr>
<td></td>
<td>Chairs: Hideo Tahmiya, Director, Biostatistics, Drug Development Division, Dainippon Sumitomo Pharma Co., Ltd., Japan, Hirokazu Saito, PhD, Manager, Biostatistics, Development Coordination Department, Mitsubishi Pharma Co., Japan</td>
</tr>
<tr>
<td></td>
<td>13:00-14:00</td>
</tr>
<tr>
<td></td>
<td>Making Statisticians Count in Drug Development: Utilizing the FDA Critical Path and EU Innovative Medicines Initiatives</td>
</tr>
<tr>
<td></td>
<td>Andrew P. Grieve, Executive Director, Statistical Research and Consulting Centre, Pfizer Global R&amp;D, UK</td>
</tr>
<tr>
<td></td>
<td>14:00-15:00</td>
</tr>
<tr>
<td></td>
<td>Role in Japan R&amp;D of Biostatistics in Evidence-based Decision Making</td>
</tr>
<tr>
<td></td>
<td>Bruce D. Forrest, MB, BS, MD, MBA, Executive Director, Research and Development, Wyeth K.K., Japan</td>
</tr>
</tbody>
</table>

Statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association. Speakers and agenda are subject to change without notice. Recording of any DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA.
## TRACK A

**Invitation to a New Era of Data and Documents**
Track Chair: Keiji Sawamukai, Manager, Data Management, Sankyo Co., Ltd., Japan

## TRACK B

**Collaboration to Fulfill Our Joint Mission of Delivering to Patients Medications of Greater Efficacy and Greater Safety with Greater Speed**
Track Chairs: Makoto Shiragami, PhD, Professor, Social and Administrative Pharmacy Science, College of Pharmacy, Nihon University, Japan and E. Stewart Geary, MD, Deputy Director, Corporate Regulatory Compliance and Quality Assurance Headquarters, Eisai Co., Ltd., Japan

## TRACK C

**Value-added Contribution of Biostatistics to Drug Development**
Track Chair: Hiroshi Maeda, Department Manager, Data Management Department, Clinical Development Division, Medical Support Business Unit, Bellsytem24, Inc., Japan

### SESSION 4

**Next Generation Authoring and Content Management**

*Track Chair: Hitoshi Matsu*, Medical and Pharmaceutical Collaborative Solution Department II, CAC Corporation, Japan; Atsushi Tomaru, PhD, Manager, Clinical Development Coordination, Kyowa Hakko Kogyo Co., Ltd., Japan

- **15:30-16:10** Managing Organizational Change for eCTD
  Carol Stretch, Senior Manager, Medical Documentation and e-Tools, Novo Nordisk Inc., USA

- **16:10-16:50** Regulatory Information Management Strategy
  Christopher M. Lee, Director, Global Regulatory Affairs and Safety, Amgen Inc., USA

- **16:50-17:30** Structured Authoring and Developing a Library of Standard Text Elements
  Karen Heraty, Consultant, Scientific Communications, Eli Lilly and Company, USA

### SESSION 5-6

**Strategic Regulatory Document Writing and Education/Training for Writers**

*Track Chair: Satomi Ando*, Director, Document Operation Department, Development Division, Novartis Pharma K.K., Japan; Haiso Fujii, DVM, PhD, Associate Director, Medical Writing, Regulatory Affairs and Safety, Amgen Limited, Japan

- **9:00-9:25** Education for Reviewers in FDA
  Nancy D. Smith, PhD, Director, Office of Training and Communications, FDA, USA

- **9:25-9:50** Academic Education for Medical Writers
  MaryAnn Foote, PhD, Vice President, Medical Writing, Abridge BioScience, Inc., USA

- **9:50-10:15** Hiring and Education of Medical Writers in Pharmaceutical Companies
  Karen Soskin, Director, Quality Systems and Training, Global Pharmaceutical Regulatory Affairs, Abbott Laboratories, USA

- **10:15-10:35** Strategic Documents Cascade of the Global Drug Development
  Fumiyu Hirano, Director, Regulatory Affairs Research and Development, Schering-Plough K.K., Japan; Yu Ichige, Manager, Project Management Department Research and Development, Schering-Plough K.K., Japan

- **10:35-11:05** What Is Our Goal for Regulatory Documents?
  Toshikazu Yoshinaga, Associate Director, Clinical Submissions Regulatory Affairs, Pfizer Japan Inc., Japan

### SESSION 3-4 continued

**Statistical Contribution to the Drug Development Strategy**

*Track Chair: Hiroki Tohmiya*, Director, Biostatistics, Drug Development Division, Daiichippon Sumitomo Pharma Co., Ltd., Japan; Hironori Sakai, PhD, Manager, Biostatistics, Development Coordination Department, Mitsubishi Pharma Co., Japan

- **15:30-16:30** When and What You Could Ask Statisticians?
  Lessons Learned from Experiences
  Koichi Funaki, Executive Director, Deputy Senior Director, Research and Development Division, Mochida Pharmaceutical Co., Ltd., Japan

- **16:30-17:30** Reconsider: What Should We Do as a Trial Statistician with Colleagues at Work for Pharmaceutical Products?
  Takashi Omori, PhD, Associate Professor, Department of Biostatistics, Kyoto University, Public Health, Japan

---

**Friday, October 6, 2006**

### TRACK A

**Invitation to a New Era of Data and Documents**
Track Chair: Keiji Sawamukai, Manager, Data Management, Sankyo Co., Ltd., Japan

### TRACK B

**Collaboration to Fulfill Our Joint Mission of Delivering to Patients Medications of Greater Efficacy and Greater Safety with Greater Speed**
Track Chairs: Makoto Shiragami, PhD, Professor, Social and Administrative Pharmacy Science, College of Pharmacy, Nihon University, Japan and E. Stewart Geary, MD, Deputy Director, Corporate Regulatory Compliance and Quality Assurance Headquarters, Eisai Co., Ltd., Japan

### TRACK C

**Value-added Contribution of Biostatistics to Drug Development**
Track Chair: Hiroshi Maeda, Department Manager, Data Management Department, Clinical Development Division, Medical Support Business Unit, Bellsytem24, Inc., Japan

### SESSION 5-6

**Education for Biostatisticians**

*Track Chair: Satoshi Morita*, PhD, Assistant Professor, Department of Epidemiology and Healthcare Research, Kyoto University Graduate School of Medicine, Japan; Yasushi Takita, Associate, Medical Statistics, Eli Lilly K.K., Japan

- **9:00-9:40** Professional and Continuing Education for Biostatisticians in Japan: An Academic Perspective
  Toshimitsu Hamasaki, PhD, Associate Professor, Department of Biomedical Statistics, Osaka University Graduate School of Medicine, Japan

- **9:40-10:20** Education/Training for Biostatisticians: A Global Industrial Perspective
  Scott Clark, PhD, Director, Nonclinical/Preclinical/Program Phase Statistics, Eli Lilly and Company, USA

- **10:20-11:00** Education/Training for Biostatisticians: A Regulatory Perspective
  Rajeshwari Subhara, PhD, Team Leader, Office of Biostatistics, Division of Biometrics V, CDER, FDA, USA

---

**Congress at a Glance continues on page 6**
12:30-12:40 Chair: Yasuo Ohashi, PhD, Professor, Department of Biostatistics, School of Health Sciences and Nursing, University of Tokyo, Japan

12:40-13:10 KEYNOTE #1
Scientific Review and Clinical Development of Advanced Therapeutics and Biologics
Koji Kawakami, MD, PhD, Professor, Department of Pharmacoepidemiology, Kyoto University Graduate School of Medicine and Public Health, Japan

13:10-13:40 KEYNOTE #2
Issue of Cooperation with Industry, Government and Academic Institute on Advanced Biomedical Research, and the Meaning of R&D Support for Bioventure Companies
Takeo Ozawa, President & CEO, POC Clinical Research Inc., Japan

13:40-14:00 Panel Discussion

14:00-14:15 Coffee Break

14:15-17:00 ASK THE REGULATORS
Current Measures for Drug Safety and Their Issues
Chairs: Makoto Shiragami, PhD, Professor, Social and Administrative Pharmacy Science, College of Pharmacy, Nihon University, Japan
E. Stewart Geary, MD, Deputy Director, Corporate Regulatory Compliance and Quality Assurance Headquarters, Eisai Co., Ltd., Japan

- Global Differences in Adverse Event Reporting Practices: An Industry Perspective
  Jennifer E. Driscoll, Director, Pharmacovigilance Management, Banyu Pharmaceutical Co., Ltd., Japan

- Problems Encountered in Compliance with Japanese Specific Safety Requirements
  Haruo Takahashi, Manager of Strategy Planning and Management, Clinical Research Center, Eisai Co., Ltd.; Chairman of PMS sub-committee of Japan Pharmaceutical Manufacturers Association (JPMA), Japan

- Measures for Drug Safety
  Yasushi Joutatsu, Deputy Director, Safety Division, Pharmaceutical and Food Safety Bureau, MHLW, Japan
  Panelists:
  Kazuhiko Mori, Director, Office of New Drug I, PMDA, Japan
  Yuki Ando, Statistical Reviewer, Office of New Drug II, PMDA, Japan

17:00 MEETING ADJOURNED

UPCOMING DIA EVENTS 2007

January 29-30, 2007    Tokyo, Japan
10th Annual Workshop in Japan for Clinical Data Management
Program Chair: Atsushi Tsujii, Amgen Limited, Japan

March 26-28, 2007    Vienna, Austria
19th Annual EuroMeeting
Program Chairs: Christa Wirthumer-Hoche, AGES PharmMed, Austria
Gerd Bode, Consultant, Germany

June 17-21, 2007    Atlanta, Georgia, USA
43rd Annual Meeting
Program Chair: Alberto Grignolo, PhD, PAREXEL Corporation, USA

October, 2007    Tokyo, Japan
The Fourth Multitrack Workshop in Japan

Drug Information Association, LLC
Level 2, Toranomon 10 Mori Building
1-18-1 Toranomon, Minato-ku, Tokyo 105-0001, Japan
TEL: +81-(0)3-5511-1131  •  FAX: +81-(0)3-5511-0100
e-mail: diajapan@diajapan.org
Third Multitrack Workshop in Japan: How Could Companies, Regulators and Academia Better Collaborate in Pharmaceutical Development?
Meeting I.D. # 06303 – October 5-6, 2006, Tokyo Conference Center-Shinagawa, AREA Shinagawa, Tokyo, Japan

REGISTRATION FEES Please check all applicable fees. If DIA cannot verify your membership upon receipt of registration form, you will be charged the nonmember fee.
Registration fee includes refreshment breaks and reception. Registrations will be accepted by mail, fax, or email.

MEMBER EARLY-BIRD OPPORTUNITY Available on nondiscount member fee only.

<table>
<thead>
<tr>
<th>Available on nondiscount member fee only.</th>
<th>On or before SEPTEMBER 6, 2006</th>
<th>On or after SEPTEMBER 7, 2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Fee</td>
<td>¥ 59,000</td>
<td>¥ 61,950</td>
</tr>
<tr>
<td>Government (Full-time)</td>
<td>¥ 25,000</td>
<td>¥ 26,250</td>
</tr>
<tr>
<td>Charitable Nonprofit/Academia (Full-Time)</td>
<td>¥ 25,000</td>
<td>¥ 26,250</td>
</tr>
</tbody>
</table>

Join DIA now to qualify for the early-bird member fee!
www.diahome.org/docs/Membership

*To qualify for the early-bird discount, registration form and accompanying payment must be received by the date above. Does not apply to government/academia/nonprofit member rates.

Nonmember Fee

<table>
<thead>
<tr>
<th>Available on nondiscount member fee only.</th>
<th>On or before SEPTEMBER 6, 2006</th>
<th>On or after SEPTEMBER 7, 2006</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government/Academia</td>
<td>¥ 10,700</td>
<td>¥ 10,700</td>
</tr>
<tr>
<td>Charitable Nonprofit/Academia</td>
<td>¥ 10,700</td>
<td>¥ 10,700</td>
</tr>
</tbody>
</table>

PAYMENT METHODS

- BANK TRANSFER TO CITIBANK, N.A., Akanaka Branch, Prudential Plaza, Nagatacho 2-13-10, Chiyoda-ku, Tokyo 100-0014, Japan. Drug Information Association Ordinary Account Number: 7585284, SWIFT CODE = CITIJPJT. Your name and company, as well as the above meeting I.D. number, must be included on the transfer document to ensure payment to your account.

Please include BANK TRANSFER REFERENCE # ___________________________________________________________

Payment by credit card is available online only – www.diahome.org

- To receive a tabletop exhibit application, please check.

Please check the applicable category below:

- Academia
- Government
- Industry
- CSO
- Student (Call for registration information)

Please complete the information below

Last Name First Name M.I. Degrees Dr. Mr. Ms.
Job Title Affiliation (Company)
Address City State Zip/Postal Country (Address as required for delivery in your country)

email (Required for emailed confirmation) *Phone Number (Required) *Fax Number

Please check one (required): I plan to spend most of my time in

- Track A
- Track B
- Track C

CANCELLATION POLICY: On or before SEPTEMBER 29, 2006 Adminstrative fee that will be withheld from refund amount:
Member/Nonmember = ¥ 21,400 Government/Academia/Nonprofit (Member/Nonmember) = ¥ 10,700

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable. DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.
【参加申込書】

第 3 回 DIA 総合ワークショップ [年会 ID#06303]
2006 年 10 月 5-6 日 東京コンフェレンスセンター・品川（東京都港区港南 1-12-1 品川）

◆ 参加申込方法
DIAホームページ(www.diahomese.org)よりお申し込み頂くか、この申込書に必要事項をご記入の上、FAXにてお申し込みください。
受理後、5営業日以内にメールにて参加確認メールを送付いたします。
＜DIA 日本事務所＞〒105-0001 東京都港区虎ノ門1-18-1 虎ノ門第一信保ビル2階 TEL:03-5511-1131 FAX:03-5511-0100＞

◆ 参加費用（該当する欄にチェックしてください）
会員資格が失効している方および非会員の方は、会員登録（更新）することにより、ワークショップへの会員費用での参加（当ワークショップも該当します）、DIA 各種機関誌の入手、DIA ウェブサイトの会員専用ページへのアクセス等、様々な特典が得られます。一時的外様がございましたら、DIA 日本事務所までお問い合わせください。参加申込みはワークショップ当日まで受け付けています。

<table>
<thead>
<tr>
<th>会員登録費</th>
<th>参加費</th>
<th>合計</th>
</tr>
</thead>
<tbody>
<tr>
<td>一般 *早期割引あり</td>
<td>￥81,950 (￥59,000) 2006年9月10日までのお申込み</td>
<td>￥81,950 (￥59,000)</td>
</tr>
<tr>
<td>￥67,200 (￥46,000) 2006年9月10日以降のお申込み</td>
<td>￥67,200 (￥46,000)</td>
<td></td>
</tr>
<tr>
<td>政府関係</td>
<td>￥26,250 (￥25,000)</td>
<td>￥26,250 (￥25,000)</td>
</tr>
<tr>
<td>非営利団体/大学関係</td>
<td>￥26,250 (￥25,000)</td>
<td>￥26,250 (￥25,000)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>会員登録する</th>
<th>非会員</th>
<th>登録費 ￥14,700(￥14,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>一般 *早期割引あり</td>
<td>￥81,950 (￥59,000) 2006年9月10日までのお申込み</td>
<td>￥81,950 (￥59,000)</td>
</tr>
<tr>
<td>￥67,200 (￥46,000) 2006年9月10日以降のお申込み</td>
<td>￥67,200 (￥46,000)</td>
<td></td>
</tr>
<tr>
<td>政府関係</td>
<td>￥26,250 (￥25,000)</td>
<td>￥26,250 (￥25,000)</td>
</tr>
<tr>
<td>非営利団体/大学関係</td>
<td>￥26,250 (￥25,000)</td>
<td>￥26,250 (￥25,000)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>非会員 (会員登録しない)</th>
<th>参加費</th>
<th>合計</th>
</tr>
</thead>
<tbody>
<tr>
<td>一般</td>
<td>￥81,950 (￥59,000)</td>
<td>￥81,950 (￥59,000)</td>
</tr>
<tr>
<td>政府関係</td>
<td>￥40,950 (￥39,000)</td>
<td>￥40,950 (￥39,000)</td>
</tr>
<tr>
<td>非営利団体/大学関係</td>
<td>￥40,950 (￥39,000)</td>
<td>￥40,950 (￥39,000)</td>
</tr>
</tbody>
</table>

◆ お支払方法
本申込書でのお支払いは、銀行振込みのみとなります。
口座番: シティバンク 赤坂支店 普通口座 7585284
口座名: Drug Information Association または ドラッグ インフォメーション アソシエーション
ご入金の際は、ご依頼人の名に必ず参加者名、年会 ID#06303、会社名の順に記載してください。同一会社で複数の方の参加費を同時に振込む場合は、書面にて参加者名と振込日を DIA 日本事務所までお知らせください。
※クレジットカードでのお支払いをご希望の方は、DIA ホームページ(www.diahomese.org)よりオンラインにてお申し込みください。

該当するカテゴリーにチェックしてください
口学校関係□政府関係□民間企業□CSO□学生（お申し込みについてはお問い合わせください）

アルファベットでご記入ください

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Name</th>
<th>Degrees</th>
<th>Dr.□Mr.□Ms.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Job Title</td>
<td>Affiliation (Company)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address</td>
<td>City</td>
<td>State</td>
<td>Zip/Postal</td>
<td>Country</td>
</tr>
<tr>
<td>Email (必須)</td>
<td>Phone Number (必須)</td>
<td>Fax Number</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

◆ 主としてご参加予定のトラック 1 つにチェックしてください (必須)
◆ 出展要綱・申込書をご希望の方は右の欄にチェックしてください □Track A □Track B □Track C □出展要綱を希望します

*参加のキャンセルは、お申込み受理後、2006年9月29日までに手数料として会員・非会員とも1,400円、政府・非営利団体/大学関係者については会員・非会員とも1,700円を申し受けます。これ以降のキャンセルについては参加費全額を申し受けますのでご了承ください。同一会社の寄付制限がある場合、その旨をお早めにお知らせください。会員資格の維持はできませんので、非会員としての参加費を申し受けの場合があります。参加のキャンセルは必ず事前に写真留保で、また、旅費のキャンセルは提供ホテルまでご連絡願います。会場は変更される場合がありますので予めご了承ください。